Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 20/20 | 0.73 |
| ▸ | THRB | P10828 | 4/20 | 0.66 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.66 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5231781 | 0.88 | TGFBR1 (0.69) | TGFBR1THRBMAPK14TGFBR2 | |
| SCHEMBL412973 | 0.87 | TGFBR1 (0.77) | TGFBR1THRBMAPK14TGFBR2 | |
| SCHEMBL373327 | 0.85 | TGFBR1 (1.00) | TGFBR1THRBMAPK14TGFBR2 | |
| SCHEMBL373221 | 0.85 | TGFBR1 (1.00) | TGFBR1THRBMAPK14TGFBR2 | |
| SCHEMBL373785 | 0.84 | TGFBR1 (1.00) | TGFBR1THRBMAPK14TGFBR2 | |
| SCHEMBL373415 | 0.83 | TGFBR1 (1.00) | TGFBR1THRBMAPK14TGFBR2 | |
| SCHEMBL5234521 | 0.83 | TGFBR1 (0.88) | TGFBR1THRBMAPK14TGFBR2 | |
| SCHEMBL5235558 | 0.83 | TGFBR1 (0.87) | TGFBR1THRBMAPK14TGFBR2 | |
| SCHEMBL5923650 | 0.83 | TGFBR1 (0.72) | TGFBR1THRBMAPK14TGFBR2 | |
| SCHEMBL412979 | 0.83 | TGFBR1 (0.88) | TGFBR1THRBMAPK14TGFBR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160115447-A1 | COMPOSITIONS AND METHODS FOR IMPROVING INDUCED NEURON GENERATION | HOWARD HUGHES MEDICAL INSTITUTE | 2016-04-28 | — | — | US | disclosed |
| WO-2014201133-A1 | COMPOSITIONS AND METHODS FOR IMPROVING INDUCED NEURON GENERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-12-18 | — | — | WO | disclosed |
| US-20140120621-A1 | TGF-BETA RECEPTOR INHIBITORS TO ENHANCE DIRECT REPROGRAMMING | THE GENERAL HOSPITAL CORPORATION (US) | 2014-05-01 | — | — | US | disclosed |
| US-8603818-B1 | TGF-beta receptor inhibitors to enhance direct reprogramming | THE GENERAL HOSPITAL CORPORATION (US) | 2013-12-10 | — | — | US | disclosed |
| US-8298825-B1 | TGF-beta receptor inhibitors to enhance direct reprogramming | THE GENERAL HOSPITAL CORPORATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120021519-A1 | EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2010033906-A2 | EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115447-A1 | COMPOSITIONS AND METHODS FOR IMPROVING INDUCED NEURON GENERATION | PLK1, GAP43, NEFM | TGFBR1 2217/4885THRB 2669/4885MAPK14 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.